Amoytop Biotech is an innovative biopharmaceutical company in China, specialized in R&D, manufacturing and marketing of regular and long-acting recombinant protein drugs. Focusing on the R&D of immune-related cytokine medicines, Amoytop Biotech is committed to providing better solutions for major diseases including viral hepatitis, malignant tumors and immunotherapy. In the future, Amoytop Biotech will specially focus on CHB (chronic hepatitis B) treatment to achieve breakthroughs in clinical cure.